(CRIS)
NCM – Real vaqt narxi. Valyuta: USD
0.56
-0.02 (-4.22%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
0.56
+0.00 (0.83%)
Bozordan keyin: Mar 27, 2026, 7:18 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
NCM – Real vaqt narxi. Valyuta: USD
0.56
-0.02 (-4.22%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
0.56
+0.00 (0.83%)
Bozordan keyin: Mar 27, 2026, 7:18 PM EDT
Curis, Inc., biotexnologiya kompaniyasi, Qo'shma Shtatlarda inson saratonini davolash uchun dori nomzodlarini kashf etish va ishlab chiqish bilan shug'ullanadi. Uning klinik bosqichidagi dori nomzodlari orasida Emavusertib, og'iz orqali qabul qilinadigan kichik molekulali IRAK4 kinaza inhibitore mavjud bo'lib, u qaytalangan yoki refrakter, yoki R/R, AML va yuqori xavfli mielodisplastik sindromlari bo'lgan bemorlarda 1/2-fazali ochiq, yagona qo'l kengaytirilgan sinovdan o'tmoqda. Kompaniyaning quvurlarida, shuningdek, qaytalangan yoki refrakter diffuz katta B-hujayrali limfomasi bo'lgan bemorlarni davolash uchun og'iz orqali qabul qilinadigan HDAC va PI3K fermentlarining er-xotin inhibitori bo'lgan Fimepinostat; PD-L1 va VISTA ni tanlab nishonga oladigan CA-170, og'iz orqali qabul qilinadigan kichik molekulali antagonist; va PD-L1 va TIM3 ning molekulali antagonisti bo'lgan CA-327, og'iz orqali qabul qilinadigan kichik molekulali TIM3/PD-L1 mavjud. Kompaniya Genentech Inc., yoki Genentech va F. Hoffmann-La Roche Ltd, yoki Roche bilan Erivedge, ilg'or bazal hujayrali karsinomani, yoki BCCni davolash uchun og'iz orqali yuboriladigan kichik molekulali hedgehog signal yo'li antagonisti; Aurigene Discovery Technologies Limited bilan immuno-onkologiya va aniq onkologiya sohalarida kichik molekulali birikmalarni kashf etish, ishlab chiqish va tijoratlashtirish bo'yicha hamkorlik shartnomalariga ega; va shuningdek, emavusertibni o'z ichiga olgan Aurigene hamkorligi doirasida uchta dasturni litsenziyalagan. Curis, Inc. 2000 yilda tashkil etilgan va uning shtab-kvartirasi Massachusets shtatining Lexington shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Ahmed M. Hamdy M.D. | Chief Medical Officer |
| Dr. Jonathan B. Zung Ph.D. | Chief Development Officer |
| Dr. Robert E. Martell M.D., Ph.D. | Chief Scientific Officer |
| Mr. James E. Dentzer | President, CEO, Secretary, Treasurer & Director |
| Mr. Mark W. Noel | Vice President of Technology Management & Intellectual Property |
| Ms. Diantha Duvall CPA, M.B.A. | CFO and Principal Financial & Accounting Officer |
| Ms. Nancy Soohoo | VP & General Counsel |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-03-19 | 8-K | cris-20260319.htm |
| 2026-03-17 | 8-K | cris-20260317.htm |
| 2026-01-08 | 8-K | cris-20260107.htm |
| 2025-11-13 | 8-K/A | cris-20251106.htm |
| 2025-11-06 | S-8 | criss-8november2025.htm |
| 2025-10-24 | 8-K | cris-20251020.htm |
| 2025-08-22 | 8-K | cris-20250821.htm |
| 2025-08-14 | CORRESP | filename1.htm |
| 2025-08-11 | S-1 | cris-sx1resaleprefundedwar.htm |
| 2025-08-08 | 8-K | cris-20250808.htm |
| Ms. Rachel Blasbalg |
| Senior Director of Human Resources |